clinical trial · NCT07080385
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Calcilytix Therapeutics, Inc., a BridgeBio company·phase3·recruiting·n = 28
Autosomal Dominant Hypocalcemia Type 1 (ADH1)Encaleret
brief summary
The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.
started
Jan 30, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2030
last updated
Apr 22, 2026
official title
A Phase 2/3, Multicenter, Single-Arm, Open-Label Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol